Patents by Inventor Bart S. Hendriks

Bart S. Hendriks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSAGE AND ADMINISTRATION FOR PREVENTING CARDIOTOXICITY IN TREATMENT WITH ERBB2-TARGETED IMMUNOLIPOSOMES COMPRISING ANTHRACYCLINE CHEMOTHERAPEUTIC AGENTS
    Publication number: 20160038416
    Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
    Type: Application
    Filed: August 20, 2015
    Publication date: February 11, 2016
    Inventors: JOSEPH G. REYNOLDS, KENNETH J. OLIVIER, JR., BART S. HENDRIKS, THOMAS WICKHAM, STEPHAN KLINZ, ELENA GERETTI
  • Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents
    Patent number: 9226966
    Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: January 5, 2016
    Assignee: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Joseph G. Reynolds, Kenneth J. Olivier, Jr., Bart S. Hendriks, Thomas Wickham, Stephan Klinz, Elena Geretti
  • MARKER QUANTITATION IN SINGLE CELLS IN TISSUE SECTIONS
    Publication number: 20150111217
    Abstract: Improved assays incorporating single-cell based image analyses that enable quantitation of expression of individual cellular proteins and heterogeneity in terms of individual cellular protein molecule numbers per cell at the single cell level and mapped across sections of clinical tissue samples are disclosed.
    Type: Application
    Filed: June 20, 2013
    Publication date: April 23, 2015
    Inventors: Bart S. Hendriks, Elena Geretti, Arthur J. Kudla, Matthew David Onsum, Violette Paragas, Sharon Moulis
  • DOSAGE AND ADMINISTRATION FOR PREVENTING CARDIOTOXICITY IN TREATMENT WITH ERBB2-TARGETED IMMUNOLIPOSOMES COMPRISING ANTHRACYCLIN CHEMOTHERAPEUTIC AGENTS
    Publication number: 20140023698
    Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
    Type: Application
    Filed: June 6, 2013
    Publication date: January 23, 2014
    Inventors: Joseph G. Reynolds, Kenneth J. Olivier, JR., Bart S. Hendriks, Thomas Wickham, Stephan Klinz, Elena Geretti
  • Polymers for delivery of nucleic acids
    Patent number: 6548302
    Abstract: The present invention relates to compositions and methods for delivery of nucleic acids. In particular, the invention provides a polymeric delivery formulation including a nucleic acid to be transfected into a host cell, formulated in a biodegradable polymer having phosphorous-based linkages.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: April 15, 2003
    Assignee: Johns Hopkins University School of Medicine
    Inventors: Hai-Quan Mao, Kevin Y. Lin, Bart S. Hendriks, Kam W. Leong, Michael F. Haller